Skip to main content
. Author manuscript; available in PMC: 2022 Sep 27.
Published in final edited form as: J Perinat Med. 2021 Apr 20;49(7):897–906. doi: 10.1515/jpm-2021-0049

Figure 2. Betamethasone treatment after intra-amniotic injection of HMGB1.

Figure 2.

(A) Experimental design: Dams were intra-amniotically injected with HMGB1 and subcutaneously treated with betamethasone (0.1 mg/100 μL) or vehicle control (saline, 100 μL) at 12 and 36 hours (h) after intra-amniotic injection, and monitored until delivery (n = 15 each). (B) Gestational length [shown as days post coitum (dpc)] of dams injected with HMGB1 and treated with vehicle (saline, red dots) or betamethasone (blue dots). Data are shown as boxplots where the midline represents the median, boxes represent interquartile range, and whiskers represent the minimum/maximum range. (C) Preterm birth rate (<19 dpc) in dams that received HMGB1 and were treated with vehicle (saline, red bar) or betamethasone (blue bar).